In Silico Pharmacokinetic Profile and Antimalarial Efficacy of 3‐Chloro‐4‐(4‐Chlorophenoxy)Aniline
Biochemistry Research International · 2026-01 · 2026 (1)
DOI: 10.1155/bri/6509347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemistry Research International, online erschienen am 02.06.2026. Verfasst von Milka W Waithera und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Biomedical Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya, jkuat.ac.ke. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Commission for Science, Technology and Innovation.
Abstract (Originalsprache)
Despite the urgent need for new therapies to treat multidrug‐resistant virulent Plasmodium falciparum , many promising antimalarial candidates fail to progress to clinical use because their pharmacokinetic (PK) profile is poorly characterized. This study predicted the PK profile of a new compound, 3‐chloro‐4‐(4‐chlorophenoxy)aniline (ANI), in silico using the pkCSM online platform. In vitro cytotoxicity in Vero E6 cells and antiplasmodial activity against chloroquine‐sensitive ( P. falciparum 3D7) and chloroquine‐resistant ( P. falciparum W2) strains were screened using the MTT colorimetric and the [ 3 H]‐hypoxanthine incorporation assays, respectively. In vivo antimalarial efficacy was evaluated in Plasmodium berghei ANKA and piperaquine‐resistant (PQ R ) P. berghei parasites in mouse models employing early and established infection tests. In silico predictions show that ANI is a substrate for CYP 3A4 and CYP 2D6 and is unlikely to inhibit the hERG potassium ion channel. ANI exhibited low cytotoxicity, with a CC 50 value of 7.90 × 10 2 ± 86.40 μM, and potent antiplasmodial activity, with IC 50 values of 1.72 ± 0.09 μM and 1.84 ± 0.21 μM against the 3D7 and W2 strains, respectively. The selectivity index of greater than 400 indicates that ANI has a broad safety margin. In vivo, ANI demonstrated antimalarial efficacy with ED 50 values of 3.07 mg/kg/day against P. berghei ANKA and 2.81 mg/kg/day against PQ R P. berghei parasites. Notably, mice treated with ANI in the established infection model survived for up to 30 days without observable adverse effects. These findings highlight ANI as a potential antimalarial compound and support further drug evaluation and development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry, School of Biomedical Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya, jkuat.ac.ke.
- Centre for Research in Infectious Diseases, Mount Kenya University, Thika, Kenya, mku.ac.ke.
- Department of Biological and Physical Sciences, School of Pure and Applied Sciences, Karatina University, Karatina, Kenya, karu.ac.ke.
ORCID-Profile: Milka W Waithera
Förderung
- National Commission for Science, Technology and Innovation
Zitieren
APA
Waithera, M. W., Kimani, S. K., Njoroge, S., Nyahanga, T., & Kinyua, J. K. (2026). In Silico Pharmacokinetic Profile and Antimalarial Efficacy of 3‐Chloro‐4‐(4‐Chlorophenoxy)Aniline. Biochemistry Research International, 2026(1). https://doi.org/10.1155/bri/6509347
Vancouver
Waithera MW, Kimani SK, Njoroge S, Nyahanga T, Kinyua JK. In Silico Pharmacokinetic Profile and Antimalarial Efficacy of 3‐Chloro‐4‐(4‐Chlorophenoxy)Aniline. Biochemistry Research International. 2026;2026(1). doi:10.1155/bri/6509347
BibTeX
@article{Waithera2026,
author = {Waithera, Milka W and Kimani, Shadrack K and Njoroge, Stephen and Nyahanga, Thomas and Kinyua, Johnson K},
title = {In Silico Pharmacokinetic Profile and Antimalarial Efficacy of 3‐Chloro‐4‐(4‐Chlorophenoxy)Aniline},
journal = {Biochemistry Research International},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/bri/6509347}
}
EUVIMED